Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD
© 2014 Maneeton et al. Results: A total of 806 final study or safety participants were included. The dosage of lisdexamfetamine was 30 to 70 mg/day. The pooled mean scores of mean change and mean end point scores between LDX- and placebo-treated groups also had a significant difference (SMD [95% CI]...
Saved in:
Main Authors: | Maneeton,N., Maneeton,B., Suttajit,S., Reungyos,J., Srisurapanont,M., Martin,S.D. |
---|---|
Format: | Article |
Published: |
Dove Medical Press Ltd.
2015
|
Subjects: | |
Online Access: | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84908066180&origin=inward http://cmuir.cmu.ac.th/handle/6653943832/38319 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Chiang Mai University |
Similar Items
-
Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: A meta-analysis of randomized, controlled trials
by: Maneeton B., et al.
Published: (2015) -
Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: A meta-analysis of randomized, controlled trials
by: Maneeton B., et al.
Published: (2015) -
Quetiapine for acute bipolar depression: A systematic review and meta-analysis
by: Sirijit Suttajit, et al.
Published: (2018) -
Comparative efficacy, acceptability, and tolerability of dexmethylphenidate versus placebo in child and adolescent ADHD: A meta-analysis of randomized controlled trials
by: Narong Maneeton, et al.
Published: (2018) -
Comparative efficacy, acceptability, and tolerability of dexmethylphenidate versus placebo in child and adolescent ADHD: A meta-analysis of randomized controlled trials
by: Narong Maneeton, et al.
Published: (2018)